OxiGene (OXGN +7.7%) says results of its Phase 2 trial of Zybrestat, a treatment for patients...
OxiGene (OXGN +7.7%) says results of its Phase 2 trial of Zybrestat, a treatment for patients with polypoidal choroidal vasculopathy, suggest that the drug, even if administered only as a single dose intravenously, may produce a transient reduction in both polyp activity and amount of subretinal fluid in patients with disease. The company also notes that further clinical testing with a more practical topical formulation in combination with photodynamic therapy may be warranted for further testing.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs